 Anna Kerege
Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Resistance | 14 | 2025 | 1222 | 1.000 |
Why?
| | Muscle, Skeletal | 11 | 2025 | 1729 | 0.640 |
Why?
| | Sphingolipids | 6 | 2024 | 77 | 0.510 |
Why?
| | Triglycerides | 4 | 2024 | 513 | 0.490 |
Why?
| | Exercise | 6 | 2025 | 2072 | 0.420 |
Why?
| | Obesity | 11 | 2025 | 2962 | 0.350 |
Why?
| | Diabetes Mellitus, Type 2 | 11 | 2023 | 2490 | 0.340 |
Why?
| | Adipose Tissue | 3 | 2025 | 643 | 0.320 |
Why?
| | Thyroid Neoplasms | 4 | 2016 | 324 | 0.270 |
Why?
| | Diglycerides | 3 | 2020 | 61 | 0.270 |
Why?
| | Lipid Metabolism | 2 | 2025 | 522 | 0.210 |
Why?
| | Fasting | 2 | 2016 | 283 | 0.200 |
Why?
| | Weight Loss | 2 | 2025 | 783 | 0.200 |
Why?
| | Prediabetic State | 2 | 2016 | 248 | 0.180 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2023 | 216 | 0.180 |
Why?
| | Blood Glucose | 6 | 2018 | 2239 | 0.170 |
Why?
| | Lipids | 1 | 2024 | 675 | 0.160 |
Why?
| | Rest | 2 | 2017 | 123 | 0.150 |
Why?
| | Glucose Clamp Technique | 4 | 2024 | 196 | 0.150 |
Why?
| | Dietary Fats | 2 | 2020 | 299 | 0.140 |
Why?
| | Athletes | 5 | 2020 | 406 | 0.130 |
Why?
| | Lipogenesis | 1 | 2017 | 61 | 0.130 |
Why?
| | Carcinoma | 2 | 2009 | 229 | 0.130 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2016 | 30 | 0.120 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 76 | 0.120 |
Why?
| | Insulin | 4 | 2024 | 2448 | 0.120 |
Why?
| | Liver | 2 | 2014 | 1805 | 0.120 |
Why?
| | Phosphatidylcholines | 1 | 2016 | 136 | 0.110 |
Why?
| | Glucose Tolerance Test | 4 | 2018 | 366 | 0.110 |
Why?
| | Glucose | 2 | 2023 | 1032 | 0.100 |
Why?
| | Ceramides | 3 | 2022 | 117 | 0.100 |
Why?
| | Benzhydryl Compounds | 1 | 2013 | 75 | 0.100 |
Why?
| | Glucose Intolerance | 1 | 2014 | 146 | 0.100 |
Why?
| | Phenols | 1 | 2013 | 104 | 0.100 |
Why?
| | Physical Endurance | 3 | 2020 | 273 | 0.090 |
Why?
| | Homeostasis | 1 | 2016 | 614 | 0.090 |
Why?
| | Adult | 13 | 2025 | 38201 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.080 |
Why?
| | Calcitriol | 1 | 2010 | 59 | 0.080 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2009 | 28 | 0.080 |
Why?
| | Sarcolemma | 2 | 2020 | 42 | 0.080 |
Why?
| | Proto-Oncogene Proteins pp60(c-src) | 1 | 2009 | 11 | 0.080 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2009 | 75 | 0.080 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 35 | 0.080 |
Why?
| | Cytosol | 2 | 2020 | 227 | 0.070 |
Why?
| | Carcinoma, Papillary | 1 | 2009 | 72 | 0.070 |
Why?
| | Humans | 20 | 2025 | 138651 | 0.070 |
Why?
| | Benzodioxoles | 1 | 2009 | 116 | 0.070 |
Why?
| | Quinazolines | 1 | 2009 | 249 | 0.070 |
Why?
| | MAP Kinase Signaling System | 1 | 2009 | 322 | 0.070 |
Why?
| | Female | 13 | 2025 | 73763 | 0.070 |
Why?
| | Male | 12 | 2025 | 68260 | 0.060 |
Why?
| | Endoplasmic Reticulum | 2 | 2020 | 265 | 0.060 |
Why?
| | Middle Aged | 7 | 2025 | 33604 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5520 | 0.060 |
Why?
| | Smoking | 1 | 2012 | 1591 | 0.060 |
Why?
| | Gene Expression Profiling | 2 | 2023 | 1746 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1388 | 0.050 |
Why?
| | Blotting, Western | 2 | 2016 | 1230 | 0.040 |
Why?
| | Cell Line, Tumor | 3 | 2016 | 3392 | 0.040 |
Why?
| | Mitochondria, Muscle | 1 | 2020 | 116 | 0.040 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 81 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 171 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2019 | 90 | 0.040 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2019 | 158 | 0.040 |
Why?
| | Mutation | 1 | 2009 | 3987 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2020 | 607 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2016 | 53 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 403 | 0.030 |
Why?
| | Phosphorylation | 2 | 2012 | 1760 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 448 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2349 | 0.030 |
Why?
| | Heterografts | 1 | 2016 | 135 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 98 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2016 | 215 | 0.030 |
Why?
| | Mice, Nude | 1 | 2016 | 688 | 0.030 |
Why?
| | Prognosis | 1 | 2023 | 3984 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1072 | 0.030 |
Why?
| | Somatostatin | 1 | 2014 | 58 | 0.030 |
Why?
| | Fructose | 1 | 2014 | 113 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 666 | 0.030 |
Why?
| | Regression Analysis | 1 | 2016 | 1017 | 0.030 |
Why?
| | Fatty Acids | 1 | 2016 | 444 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2016 | 710 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2012 | 60 | 0.020 |
Why?
| | Exercise Test | 1 | 2015 | 622 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4092 | 0.020 |
Why?
| | Cell Proliferation | 2 | 2009 | 2480 | 0.020 |
Why?
| | Mitochondria | 1 | 2018 | 955 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 665 | 0.020 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 2010 | 14 | 0.020 |
Why?
| | Steroid Hydroxylases | 1 | 2010 | 19 | 0.020 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2010 | 15 | 0.020 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 17 | 0.020 |
Why?
| | Retinoid X Receptors | 1 | 2010 | 38 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2014 | 358 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3523 | 0.020 |
Why?
| | Signal Transduction | 2 | 2016 | 5086 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 347 | 0.020 |
Why?
| | Butadienes | 1 | 2009 | 37 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2590 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 415 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2009 | 193 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2012 | 555 | 0.020 |
Why?
| | Nitriles | 1 | 2009 | 176 | 0.020 |
Why?
| | Benzamides | 1 | 2009 | 213 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2009 | 195 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 623 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 810 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 1123 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2009 | 956 | 0.020 |
Why?
| | Vitamin D | 1 | 2010 | 393 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2174 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 364 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2030 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 847 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 359 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 801 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2009 | 907 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 2225 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5798 | 0.010 |
Why?
| | Animals | 2 | 2016 | 37217 | 0.010 |
Why?
| | Mice | 1 | 2016 | 17814 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 2152 | 0.010 |
Why?
| | Young Adult | 1 | 2012 | 13305 | 0.010 |
Why?
|
|
Kerege's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|